BioStock: Cereno Scientific is shifting gears

When the US FDA granted the Orphan Drug Designation for CS1 in Pulmonary Arterial Hypertension, Cereno Scientific opened a door to new possibilities and attractive opportunities. Now, the company has decided to refocus its development efforts for its lead candidate CS1 to rare disease PAH, which they say will optimize the opportunities for the company as well as its shareholders. As a confirmation of the investor community’s high hopes for the project, Cereno Scientific also announced that they have raised 60 million SEK in a directed share issue.

Read the full article at biostock.se:

https://www.biostock.se/en/cereno-scientific-is-shifting-gears/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se